Wednesday, October 24, 2012

QVA149 filed in Europe - Triggers $5m in milestone payments to Sosei

QVA149 an investigational inhaled, once-daily, fixed-dose combination of indacaterol (LABA)
maleate and glycopyrronium bromide (NVA237 - LAMA) haas been filed for marketing authorisation with the European Medicines Agency (EMA). The filing triggers a $5m milestone payment to Sosei.

Enter your email address:


Delivered by FeedBurner